Currently, several clinicopathological factors, such as prostate-specific antigen (PSA), Gleason score, and cancer stage, have been concluded as predictors for the efficacy of ADT, but patient prognosis remains heterogeneous. The gene discussed is KLK3; the disease is cancer.